SABCS 2022 | TAXIS: axillary dissection to determine nodal burden to inform systemic therapy in node-positive BC

Walter P. Weber, MD, University Hospital Basel, Basel, Switzerland, provides and overview a pre-planned substudy of the Phase III TAXIS (NCT03513614) trial investigating axillary dissection to determine nodal burden to inform systemic therapy recommendations in patients with clinically node-positive breast cancer. Patients were randomized after tailored axillary surgery (TAS) to undergo axillary lymph node dissection or axillary radiotherapy without axillary lymph node dissection. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.